Overview

A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within Scandinavia

Status:
Completed
Trial end date:
1993-12-01
Target enrollment:
Participant gender:
Summary
PhXA41 is not inferior to timolol in reducing intra-ocular pressure
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Latanoprost
Timolol